SCHEMBL19328142

SCHEMBL19328142

CC(C)(C)CNCC=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4959977 0.74
SCHEMBL112567 0.73 TSHR (0.36)
SCHEMBL19496797 0.72
SCHEMBL8391681 0.71
SCHEMBL24141884 0.70
SCHEMBL17722541 0.70 KDM1A (0.31)
SCHEMBL12826510 0.70 KDM1A (0.36)
SCHEMBL17722544 0.70 KDM1A (0.31)
Fluoride SCHEMBL22032650 0.70 TSHR (0.33)
Hydrochloric Acid SCHEMBL4316309 0.70 TSHR (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12544338-B2 Solid or semisolid lipid based dosage form stabilization through curing and addition of low HLB surfactant(s) R.P. SCHERER TECHNOLOGIES, LLC (US) 2026-02-10 US disclosed
WO-2025264247-A1 THERMOPLASTIC BLENDS FOR INJECTION MOLDING PLANTSWITCH, INC (US) 2025-12-26 WO disclosed
WO-2025264246-A1 THERMOPLASTIC BLENDS FOR INJECTION MOLDING PLANTSWITCH, INC (US) 2025-12-26 WO disclosed
US-12434891-B2 Degradable materials and packaging made from same MONOSOL, LLC (US) 2025-10-07 US disclosed
EP-4543455-A2 METHODS OF TREATING NEUROLOGICAL VENTILATORY INSUFFICIENCY Enalare Therapeutics Inc. (US) 2025-04-30 EP disclosed
WO-2025080559-A1 METHODS AND COMPOSITIONS FOR TREATING DRUG OVERDOSE ENALARE THERAPEUTICS INC. (US) 2025-04-17 WO disclosed
US-20250114370-A1 METHODS AND COMPOSITIONS FOR TREATING DRUG OVERDOSE ENALARE THERAPEUTICS INC (US) 2025-04-10 US disclosed
EP-4504206-A2 RESPIRATORY STIMULANT NASAL FORMULATIONS Enalare Therapeutics Inc. (US) 2025-02-12 EP disclosed
US-20250031718-A1 NICOTINAMIDE ADENINE DINUCLEOTIDE (NAD) COMPOSITIONS, METHODS OF MANUFACTURING THEREOF, AND METHODS OF USE THEREOF SOVIDA SOLUTIONS LTD (GB) 2025-01-30 US disclosed
US-20250032496-A1 METHODS OF TREATING RESPIRATORY DEPRESSION MODULATED BY A NON-OPIOID AGENT ENALARE THERAPEUTICS INC (US) 2025-01-30 US disclosed
WO-2022197581-A1 NON-ORAL MEDICATED CANNABINOID COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS OF TREATMENT TAURIGA SCIENCES INC. (US) 2022-09-22 WO disclosed
US-20220296561-A1 NON-ORAL MEDICATED CANNABINOID COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS OF TREATMENT TAURIGA SCIENCES INC (US) 2022-09-22 US disclosed
EP-4051203-A1 SUPPOSITORY CAPSULE R.P. Scherer Technologies, LLC (US) 2022-09-07 EP disclosed
US-20220017276-A1 DEGRADABLE MATERIALS AND PACKAGING MADE FROM SAME MONOSOL, LLC 2022-01-20 US disclosed
US-20210308062-A1 SOLID OR SEMISOLID LIPID BASED DOSAGE FORM STABILIZATION THROUGH CURING AND ADDITION OF LOW HLB SURFACTANT(S) ARES CAPITAL CORPORATION, AS COLLATERAL AGENT 2021-10-07 US disclosed
WO-2021188612-A1 MEDICATED CANNABINOID COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS OF TREATMENT TAURIGA SCIENCES INC. (US) 2021-09-23 WO disclosed
US-20210290564-A1 MEDICATED CANNABINOID COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS OF TREATMENT TAURIGA SCIENCES INC. 2021-09-23 US disclosed
EP-3846852-A1 SOLID OR SEMISOLID LIPID BASED DOSAGE FORM STABILIZATION THROUGH CURING AND ADDITION OF LOW HLB SURFACTANT(S) R.P. Scherer Technologies, LLC (US) 2021-07-14 EP disclosed
WO-2021087210-A1 SUPPOSITORY CAPSULE R.P. SCHERER TECHNOLOGIES, LLC (US) 2021-05-06 WO disclosed
US-20170259976-A1 DEGRADABLE MATERIALS AND PACKAGING MADE FROM SAME MONOSOL, LLC (US) 2017-09-14 US disclosed